Basic Information

Common name
B-hCD24 MC38
Catalog number
Colon carcinoma
Tissue types

Targeting strategy

Gene targeting strategy for B-hCD24 MC38 cells. The exogenous promoter and human CD24 coding sequence was inserted to replace part of murine exon 1 and all of exon 2. The insertion disrupts the endogenous murine Cd24 gene, resulting in a non-functional transcript.

Protein expression analysis

CD24 expression analysis in B-hCD24 MC38 cells by flow cytometry. Single cell suspensions from wild-type MC38 and B-hCD24 MC38 cultures were stained with species-specific anti-CD24 antibody. Human CD24 was detected on the surface of B-hCD24 MC38 cells but not wild-type MC38 cells. The 1-F02 clone of B-hCD24 MC38 cells was used for in vivo experiments.

Tumor growth curve & Body weight changes

Subcutaneous homograft tumor growth of B-hCD24 MC38 cells. B-hCD24 MC38 cells (1×106) and wild-type MC38 cells (1×106) were subcutaneously implanted into C57BL/6 mice (female, 6-7-week-old, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5 × long diameter × short diameter2. As shown in panel A, B-hCD24 MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.

Tumor volume and weight measurements

Protein expression analysis of tumor cells

B-hCD24 MC38 cells were subcutaneously transplanted into C57BL/6 mice (n=5), and on 34 days post inoculation, tumor cells were harvested and assessed for human CD24 expression by flow cytometry. As shown, human CD24 was highly expressed on the surface of tumor cells. Therefore, B-hCD24 MC38 cells can be used for in vivo efficacy studies of novel CD24 therapeutics.